Temitayo Ajayi Selected Research

Hypersensitivity (Allergy)

1/2021	Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
12/2018	Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Temitayo Ajayi Research Topics

Disease

5	Acute Lung Injury 05/2009 - 08/2003
4	Pneumonia (Pneumonitis) 05/2009 - 02/2004
3	Hemolysis 01/2023 - 01/2021
3	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 12/2019 - 01/2018
2	Rare Diseases (Rare Disease) 01/2023 - 01/2021
2	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2023 - 01/2021
2	Fatigue 09/2022 - 01/2021
2	Chronic Disease (Chronic Diseases) 09/2022 - 01/2021
2	Injection Site Reaction 09/2022 - 01/2021
2	Hypersensitivity (Allergy) 01/2021 - 12/2018
2	Epilepsy (Aura) 01/2021 - 01/2018
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 01/2019
2	Infections 01/2018 - 06/2010
2	Cystic Fibrosis (Mucoviscidosis) 07/2014 - 11/2010
1	Deglutition Disorders (Dysphagia) 01/2023
1	Dyspnea (Shortness of Breath) 01/2023
1	Airway Obstruction (Choking) 01/2023
1	Oropharyngeal Neoplasms 01/2023
1	Anemia 01/2023
1	Nasopharyngitis 09/2022
1	Diarrhea 01/2021
1	Fever (Fevers) 01/2021
1	Headache (Headaches) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Disease Progression 12/2019
1	Dementia (Dementias) 01/2018
1	Acute Kidney Injury (Acute Renal Failure) 07/2014
1	Inborn Genetic Diseases (Disease, Hereditary) 07/2014
1	Pulmonary Edema 05/2009
1	Sepsis (Septicemia) 02/2004

Drug/Important Bio-Agent (IBA)

4	Tripeptidyl-Peptidase 1IBA 01/2021 - 01/2018
3	pegcetacoplanIBA 01/2023 - 01/2021
3	EnzymesIBA 01/2021 - 01/2018
3	Proteins (Proteins, Gene)FDA Link 07/2014 - 06/2010
3	Type III Secretion SystemsIBA 06/2010 - 04/2004
2	Complement System Proteins (Complement)IBA 01/2023 - 01/2021
2	eculizumab FDA Link 09/2022 - 01/2021
2	cerliponase alfaIBA 01/2021 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 12/2019 - 05/2009
2	atalurenIBA 07/2014 - 11/2010
2	Nonsense Codon (Nonsense Mutation)IBA 07/2014 - 11/2010
1	Complement Inactivating AgentsIBA 01/2023
1	AntibodiesIBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Immunoglobulin E (IgE)IBA 12/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	Tobramycin (Nebcin)FDA LinkGeneric 07/2014
1	ChloridesIBA 07/2014
1	CreatinineIBA 07/2014
1	Messenger RNA (mRNA)IBA 11/2010
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 11/2010
1	Cytotoxins (Cytolysins)IBA 06/2010
1	Plasminogen Activators (Plasminogen Activator)IBA 05/2009
1	Plasminogen Activator Inhibitor 1IBA 05/2009
1	Phospholipases (Phospholipase)IBA 11/2004
1	Toll-Like Receptor 4IBA 02/2004
1	LipopolysaccharidesIBA 02/2004
1	Immunoglobulin Fab FragmentsIBA 08/2003

Therapy/Procedure

5	Therapeutics 01/2023 - 08/2003
3	Radiotherapy 01/2023 - 01/2019
1	Aftercare (After-Treatment) 01/2023
1	Enzyme Replacement Therapy 01/2018
1	Mechanical Ventilators (Ventilator) 05/2009